Cellerant Therapeutics Inc. said Thursday it has received an additional $16.7 million in funding to help the company advance its development to treat Acute Radiation Syndrome or radiation poisoning.
The capital comes from the Biomedical Advanced Research and Development Authority in the Office of the Assistant Secretary for Preparedness and Response of the U.S. Department of Health and Human Services.
No comments:
Post a Comment